Austar LifesciencesAULSF -71.43%49 Gross Margin % is 17.74% as of Dec. 2025, which is 24% below its 10-year median of 23.21. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 89.94% on this metric.
Austar Lifesciences Ltd gross margin has been in long-term decline. The average rate of decline per year is -5.6%.
The historical rank and industry rank for Austar Lifesciences's Gross Margin % or its related term are showing as below:
AULSF'
s Gross Margin % Range Over the Past 10 Years
Min: 19.05 Med: 23.21 Max: 27.1
Current: 19.15
During the past 13 years, the highestGross Margin % of Austar Lifesciences was 27.10%. The lowest was 19.05%. And the median was 23.21%.
AULSF's Gross Margin % is ranked worse than 89.94% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs AULSF: 19.15
Austar Lifesciences had a gross margin of 17.74% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Austar Lifesciences was -5.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Austar Lifesciences had a gross margin of 17.74% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Austar Lifesciences Gross Margin % Related Terms
Austar Lifesciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Austar Lifesciences (AULSF) has a Gross Margin % of 17.74% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Austar Lifesciences and its competitors. This is 24% below median its historical median of 23.21. Over the past decade, Austar Lifesciences' Gross Margin % has ranged from 19.05 to 27.10. According to the industry distribution chart, Austar Lifesciences ranks #724 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is Austar Lifesciences' Gross Margin % too high?
Austar Lifesciences' current Gross Margin % of 17.74% is 24% below median its 10-year median of 23.21. Over the past 10 years, this metric has ranged from a low of 19.05 to a high of 27.10. The Medical Devices & Instruments industry median Gross Margin % is 51.94. Austar Lifesciences' value of 17.74% is 65.8% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #724 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #724 out of 805 companies for Gross Margin %. This places Austar Lifesciences in the lower half of its industry. The industry median Gross Margin % is 51.94. Austar Lifesciences' value of 17.74% is 65.8% below this benchmark. Historically, Austar Lifesciences' own Gross Margin % has ranged from 19.05 to 27.10 over the past decade. While the company's 10-year median is 23.21 vs. the industry median of 51.94, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Gross Margin % of 17.74% is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Gross Margin % is 17.74%, which is 24% below median its own 10-year median of 23.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Gross Margin % of 17.74%. The stock's GF Value™ is $0.10, compared to a current price of $0.02 — trading 80% below its estimated fair value. The current Gross Margin % is 17.74%, which is 24% below median its 10-year median of 23.21 and 65.8% below the Medical Devices & Instruments industry median of 51.94. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Gross Margin % is 17.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 80% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
Gross Margin %: 17.74% (24% below median its 10-year median of 23.21)
GF Value™: $0.10 vs. price of $0.02 (80% below fair value)
Industry Position: 65.8% below the Medical Devices & Instruments median (#724 of 805)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
